SRPT - Sarepta gains after Pfizer's late-stage setback for Duchenne therapy
2024-06-13 07:00:26 ET
More on Pfizer, Roche, etc.
- Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
- Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- Pfizer: Surging Cancer Rates Will Boost Revenues
- Pfizer Duchenne muscular dystrophy gene therapy fails in phase 3
- Pfizer, Flagship to collaborate on obesity drug discovery